-

bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024, at 8:00 a.m. ET.

To access the live conference call via telephone, please register at this link to receive a dial in number and unique PIN.

The live webcast of the call may be accessed by visiting the “Events & Presentations” page within the Investors & Media section of the bluebird website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird website for 90 days following the event.

About bluebird bio, Inc.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.

With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

Contacts

Investors:
Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com

Media:
Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com

Industry:

bluebird bio, Inc.

NASDAQ:BLUE
Release Versions
English

Contacts

Investors:
Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com

Media:
Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com

More News From bluebird bio, Inc.

Genetix Presents Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation at the 67th American Society of Hematology (ASH) Annual Meeting

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced real-world data from the commercial implementation of ZYNTEGLO™ and LYFGENIA™, first-in-class ex vivo gene addition therapies for the treatment of beta-thalassemia and sickle cell disease. With over 250 patients treated with these therapies, inclusive of clinical trials and commercial treatments, and long-term follow-up data beyond 10 years, Genetix has the most robust long-term dataset in ex vivo gene therapy for...

Genetix Participates in the American Society of Hematology’s (ASH) Exclusive Press Program & Shares Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced their participation in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67th ASH annual meeting in Orlando, Florida (December 6-9, 2025). Genetix’s abstract Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia was selected by the ASH Program Committee as one of the meeting’s most impactful datasets sub...

Genetix Biotherapeutics to Present Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation at the 67th American Society of Hematology (ASH) Annual Meeting

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced that an analysis of recent patient experience data from the commercial implementation of LYFGENIA™ and ZYNTEGLO™ in the U.S. has been selected for oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida (December 6-9, 2025). “We are pleased to share this analysis for the first time at ASH, which demonstrates the rising acceptance and administration of our one-time gene...
Back to Newsroom